Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 9/2021

01-09-2021 | Cefoxitin | Review Article

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis

Authors: Andrew Burke, Daniel Smith, Chris Coulter, Scott C. Bell, Rachel Thomson, Jason A. Roberts

Published in: Clinical Pharmacokinetics | Issue 9/2021

Login to get access

Abstract

Non-tuberculous mycobacteria (NTM) are an emerging group of pulmonary infectious pathogens of increasing importance to the management of patients with cystic fibrosis (CF). NTM include slow-growing mycobacteria such as Mycobacterium avium complex (MAC) and rapidly growing mycobacteria such as Mycobacterium abscessus. The incidence of NTM in the CF population is increasing and infection contributes to significant morbidity to the patient and costs to the health system. Treating M. abscessus requires the combination of multiple costly antibiotics for months, with potentially significant toxicity associated with treatment. Although international guidelines for the treatment of NTM infection in CF are available, there are a lack of robust pharmacokinetic studies in CF patients to inform dosing and drug choice. This paper aims to outline the pharmacokinetic and pharmacodynamic factors informing the optimal treatment of NTM infections in CF.
Literature
1.
Bulitta JB, Jiao Y, Drescher SK, Oliver A, Louie A, Moya B, et al. Four decades of beta-lactam antibiotic pharmacokinetics in cystic fibrosis. Clin Pharmacokinet. 2019;58(2):143–56.PubMedCrossRef
2.
Rivosecchi RM, Samanta P, Demehin M, Nguyen MH. Pharmacokinetics of azole antifungals in cystic fibrosis. Mycopathologia. 2018;183(1):139–50.PubMedCrossRef
3.
Rey E, Treluyer JM, Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet. 1998;35(4):313–29.PubMedCrossRef
4.
Prandota J. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs. 1988;35(5):542–78.PubMedCrossRef
5.
Kalscheuer R, Palacios A, Anso I, Cifuente J, Anguita J, Jacobs WR Jr, et al. The Mycobacterium tuberculosis capsule: a cell structure with key implications in pathogenesis. Biochem J. 2019;476(14):1995–2016.PubMedCrossRef
6.
Adjemian J, Olivier KN, Prevots DR. Epidemiology of pulmonary nontuberculous Mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010–2014. Ann Am Thorac Soc. 2018;15(7):817–26.PubMedPubMedCentralCrossRef
7.
Leung JM, Olivier KN. Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis. Curr Opin Pulm Med. 2013;19(6):662–9.PubMedPubMedCentralCrossRef
8.
Ratnatunga CN, Lutzky VP, Kupz A, Doolan DL, Reid DW, Field M, et al. The rise of non-tuberculosis mycobacterial lung disease. Front Immunol. 2020;11:303.PubMedPubMedCentralCrossRef
9.
Sherrard LJ, Tay GT, Butler CA, Wood ME, Yerkovich S, Ramsay KA, et al. Tropical Australia is a potential reservoir of non-tuberculous mycobacteria in cystic fibrosis. Eur Respir J. 2017;49(5):1700046.PubMedCrossRef
10.
Gardner AI, McClenaghan E, Saint G, McNamara PS, Brodlie M, Thomas MF. Epidemiology of nontuberculous mycobacteria infection in children and young people with cystic fibrosis: analysis of UK cystic fibrosis registry. Clin Infect Dis. 2019;68(5):731–7.PubMedCrossRef
11.
Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016;71(Suppl 1):i1-22.PubMedCrossRef
12.
Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). BMJ open respiratory research. 2017;4(1):e000242.PubMedPubMedCentralCrossRef
13.
Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416.PubMedCrossRef
14.
Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. Thorax. 2016;71(1):88–90.PubMedCrossRef
15.
Koh WJ, Jeong BH, Jeon K, Kim SY, Park KU, Park HY, et al. Oral macrolide therapy following short-term combination antibiotic treatment for Mycobacterium massiliense lung disease. Chest. 2016;150(6):1211–21.PubMedCrossRef
16.
Koh WJ, Jeong BH, Kim SY, Jeon K, Park KU, Jhun BW, et al. Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease. Clin Infect Dis. 2017;64(3):309–16.PubMedCrossRef
17.
Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(Suppl 2):ii1–64.PubMedCrossRef
18.
Goutelle S, Bourguignon L, Maire P, Jelliffe RW, Neely MN. The case for using higher doses of first line anti-tuberculosis drugs to optimize efficacy. Curr Pharm Des. 2014;20(39):6191–206.PubMedCrossRef
19.
Sekaggya-Wiltshire C, Lamorde M, Kiragga AN, Dooley KE, Kamya MR, Kambugu A, et al. The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs. Tuberculosis (Edinburgh). 2018;108:77–82.CrossRef
20.
Fernandez-Roblas R, Martin-de-Hijas NZ, Fernandez-Martinez AI, Garcia-Almeida D, Gadea I, Esteban J. In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. Antimicrob Agents Chemother. 2008;52(11):4184–6.PubMedPubMedCentralCrossRef
21.
van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012;186(6):559–65.PubMedCrossRef
22.
Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline: executive summary. Clin Infect Dis. 2020;71(4):905–13.PubMedPubMedCentralCrossRef
23.
Schon T, Matuschek E, Mohamed S, Utukuri M, Heysell S, Alffenaar JW, et al. Standards for MIC testing that apply to the majority of bacterial pathogens should also be enforced for Mycobacterium tuberculosis complex. Clin Microbiol Infect. 2019;25(4):403–5.PubMedPubMedCentralCrossRef
24.
Li L, Somerset S. Digestive system dysfunction in cystic fibrosis: challenges for nutrition therapy. Dig Liver Dis. 2014;46(10):865–74.PubMedCrossRef
25.
Molloy L, Nichols K. Infectious Diseases Pharmacotherapy for Children With Cystic Fibrosis. J Pediatric Health Care. 2015;29(6):565–78 (quiz 79–80).CrossRef
26.
Oshikoya KA, Senbanjo IO. Pathophysiological changes that affect drug disposition in protein-energy malnourished children. Nutr Metab. 2009;6:50.CrossRef
27.
Vinks AA, van Rossem RN, Mathot RA, Heijerman HG, Mouton JW. Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. Antimicrob Agents Chemother. 2007;51(9):3049–55.PubMedPubMedCentralCrossRef
28.
Oshikoya KA, Senbanjo IO. Caution when treating tuberculosis in malnourished children. Arch Dis Child. 2018;103(12):1101–3.PubMedCrossRef
29.
Oshikoya KA, Sammons HM, Choonara I. A systematic review of pharmacokinetics studies in children with protein-energy malnutrition. Eur J Clin Pharmacol. 2010;66(10):1025–35.PubMedCrossRef
30.
Beringer P, Huynh KM, Kriengkauykiat J, Bi L, Hoem N, Louie S, et al. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. Antimicrob Agents Chemother. 2005;49(12):5013–7.PubMedPubMedCentralCrossRef
31.
Beringer PM, Owens H, Nguyen A, Benitez D, Rao A, D’Argenio DZ. Pharmacokinetics of doxycycline in adults with cystic fibrosis. Antimicrob Agents Chemother. 2012;56(1):70–4.PubMedPubMedCentralCrossRef
32.
Healy DP, Brodbeck MC, Clendening CE. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother. 1996;40(1):6–10.PubMedPubMedCentralCrossRef
33.
34.
Leeuwen L, Fitzgerald DA, Gaskin KJ. Liver disease in cystic fibrosis. Paediatr Respir Rev. 2014;15(1):69–74.PubMed
35.
Haack A, Aragao GG, Novaes MR. Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases. World J Gastroenterol. 2013;19(46):8552–61.PubMedPubMedCentralCrossRef
36.
Brater DC. Measurement of renal function during drug development. Br J Clin Pharmacol. 2002;54(1):87–95.PubMedCrossRef
37.
38.
Prestidge C, Chilvers MA, Davidson AG, Cho E, McMahon V, White CT. Renal function in pediatric cystic fibrosis patients in the first decade of life. Pediatr Nephrol. 2011;26(4):605–12.PubMedCrossRef
39.
Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, Sherwin CM, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. Pediatric Pulmonol. 2013;48(2):107–22.CrossRef
40.
Touw DJ. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm World Sci. 1998;20(4):149–60.PubMedCrossRef
41.
Reed MD, Stern RC, O’Brien CA, Yamashita TS, Myers CM, Blumer JL. Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis. Antimicrob Agents Chemother. 1985;27(4):583–8.PubMedPubMedCentralCrossRef
42.
Bulitta JB, Landersdorfer CB, Hüttner SJ, Drusano GL, Kinzig M, Holzgrabe U, et al. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother. 2010;54(3):1275–82.PubMedPubMedCentralCrossRef
43.
Hong LT, Liou TG, Deka R, King JB, Stevens V, Young DC. Pharmacokinetics of continuous infusion beta-lactams in the treatment of acute pulmonary exacerbations in adult patients with cystic fibrosis. Chest. 2018;154(5):1108–14.PubMedPubMedCentralCrossRef
44.
Rogers JD, Meisinger MA, Ferber F, Calandra GB, Demetriades JL, Bland JA. Pharmacokinetics of imipenem and cilastatin in volunteers. Rev Infect Dis. 1985;7(Suppl 3):S435–46.PubMedCrossRef
45.
Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs. 1996;51(1):99–136.PubMedCrossRef
46.
Primaxin(Imipenem/Cilastatin) [product Insert], Whitehouse Station: Merck and Co.; 2006.
47.
Rizk ML, Rhee EG, Jumes PA, Gotfried MH, Zhao T, Mangin E, et al. Intrapulmonary pharmacokinetics of relebactam, a novel beta-lactamase inhibitor, dosed in combination with imipenem-cilastatin in healthy subjects. Antimicrob Agents Chemother. 2018;62(3):e01411-e1417.PubMedPubMedCentralCrossRef
48.
Lavollay M, Dubee V, Heym B, Herrmann JL, Gaillard JL, Gutmann L, et al. In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex. Clin Microbiol Infect. 2014;20(5):O297-300.PubMedCrossRef
49.
Brown-Elliott BA, Killingley J, Vasireddy S, Bridge L, Wallace RJ Jr. In vitro comparison of ertapenem, meropenem, and imipenem against isolates of rapidly growing mycobacteria and nocardia by use of broth microdilution and etest. J Clin Microbiol. 2016;54(6):1586–92.PubMedPubMedCentralCrossRef
50.
Luthra S, Rominski A, Sander P. The role of antibiotic-target-modifying and antibiotic-modifying enzymes in Mycobacterium abscessus drug resistance. Front Microbiol. 2018;9:2179.PubMedPubMedCentralCrossRef
51.
Story-Roller E, Maggioncalda EC, Cohen KA, Lamichhane G. Mycobacterium abscessus and beta-Lactams: emerging insights and potential opportunities. Front Microbiol. 2018;9:2273.PubMedPubMedCentralCrossRef
52.
Kaushik A, Ammerman NC, Lee J, Martins O, Kreiswirth BN, Lamichhane G, et al. In vitro activity of the new beta-lactamase inhibitors relebactam and vaborbactam in combination with beta-lactams against Mycobacterium abscessus complex clinical isolates. Antimicrob Agents Chemother. 2019;63(3):e02623-e2718.PubMedPubMedCentralCrossRef
53.
Clinical and Laboratory Standards Institute (CLSI). Performance standards for suscetibility testing of Mycobacteria, Nocardia spp., and other aerobic actinomycetes. Wayne: CLSI; 2018.
54.
Carver PL, Nightingale CH, Quintiliani R. Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers. J Antimicrob Chemother. 1989;23(1):99–106.PubMedCrossRef
55.
Perea EJ, Garcia-Iglesias MC, Ayarra J, Loscertales J. Comparative concentrations of cefoxitin in human lungs and sera. Antimicrob Agents Chemother. 1983;23(2):323–4.PubMedPubMedCentralCrossRef
56.
Moine P, Mueller SW, Schoen JA, Rothchild KB, Fish DN. Pharmacokinetic and pharmacodynamic evaluation of a weight-based dosing regimen of cefoxitin for perioperative surgical prophylaxis in obese and morbidly obese patients. Antimicrob Agents Chemother. 2016;60(10):5885–93.PubMedPubMedCentralCrossRef
57.
Ferro BE, van Ingen J, Wattenberg M, van Soolingen D, Mouton JW. Time-kill kinetics of antibiotics active against rapidly growing mycobacteria. J Antimicrob Chemother. 2015;70(3):811–7.PubMedCrossRef
58.
Clinical and Laboratories Standards Institute. CLSI susceptibility of mycobacteria, noacardiae, and other aerobic actinomycetes: approved standard—second edition CLSI Document M24–A2. Wayne: CLSI; 2011.
59.
Czaja CA, Levin A, Moridani M, Krank JL, Curran-Everett D, Anderson PL. Cefoxitin continuous infusion for lung infection caused by the Mycobacterium abscessus group. Antimicrob Agents Chemother. 2014;58(6):3570–1.PubMedPubMedCentralCrossRef
60.
Perks SJ, Lanskey C, Robinson N, Pain T, Franklin R. Systematic review of stability data pertaining to selected antibiotics used for extended infusions in outpatient parenteral antimicrobial therapy (OPAT) at standard room temperature and in warmer climates. Eur J Hosp Pharm. 2020;27(2):65–72.PubMedCrossRef
61.
Stiles ML, Tu YH, Allen LV Jr. Stability of cefazolin sodium, cefoxitin sodium, ceftazidime, and penicillin G sodium in portable pump reservoirs. Am J Hosp Pharm. 1989;46(7):1408–12.PubMed
62.
Jeon K, Kwon OJ, Lee NY, Kim BJ, Kook YH, Lee SH, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med. 2009;180(9):896–902.PubMedCrossRef
63.
Yagi K, Ishii M, Namkoong H, Asami T, Iketani O, Asakura T, et al. The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases. BMC Infect Dis. 2017;17(1):558.PubMedPubMedCentralCrossRef
64.
65.
Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018;198(12):1559–69.PubMedCrossRef
66.
Olivier KN, Griffith DE, Eagle G, McGinnis JP 2nd, Micioni L, Liu K, et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2017;195(6):814–23.PubMedPubMedCentralCrossRef
67.
Khan O, Chaudary N. The use of amikacin liposome inhalation suspension (Arikayce) in the treatment of refractory nontuberculous mycobacterial lung disease in adults. Drug Des Dev Ther. 2020;14:2287–94.CrossRef
68.
Zhang J, Leifer F, Rose S, Chun DY, Thaisz J, Herr T, et al. Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages. Front Microbiol. 2018;9:915.PubMedPubMedCentralCrossRef
69.
70.
Weers J, Metzheiser B, Taylor G, Warren S, Meers P, Perkins WR. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv. 2009;22(2):131–8.PubMedCrossRef
71.
Okusanya OO, Bhavnani SM, Hammel J, Minic P, Dupont LJ, Forrest A, et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother. 2009;53(9):3847–54.PubMedPubMedCentralCrossRef
72.
Ellender CM, Law DB, Thomson RM, Eather GW. Safety of IV amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease. Respirology. 2016;21(2):357–62.PubMedCrossRef
73.
Sturkenboom MGG, Simbar N, Akkerman OW, Ghimire S, Bolhuis MS, Alffenaar JC. Amikacin dosing for MDR tuberculosis: a systematic review to establish or revise the current recommended dose for tuberculosis treatment. Clin Infect Dis. 2018;67(Suppl 3):S303–7.PubMedCrossRef
74.
Srivastava S, Modongo C, Siyambalapitiyage Dona CW, Pasipanodya JG, Deshpande D, Gumbo T. Amikacin optimal exposure targets in the hollow-fiber system model of tuberculosis. Antimicrob Agents Chemother. 2016;60(10):5922–7.PubMedPubMedCentralCrossRef
75.
Caceres Guido P, Perez M, Halac A, Ferrari M, Ibarra M, Licciardone N, et al. Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis. Pediatr Pulmonol. 2019;54(11):1801–10.PubMedCrossRef
76.
Nolt VD, Pijut KD, Autry EB, Williams WC, Burgess DS, Burgess DR, et al. Amikacin target achievement in adult cystic fibrosis patients utilizing Monte Carlo simulation. Pediatr Pulmonol. 2019;54(1):33–9.PubMedCrossRef
77.
Ferro BE, Srivastava S, Deshpande D, Sherman CM, Pasipanodya JG, van Soolingen D, et al. Amikacin pharmacokinetics/pharmacodynamics in a novel hollow-fiber mycobacterium abscessus disease model. Antimicrob Agents Chemother. 2015;60(3):1242–8.PubMedCrossRef
78.
Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, et al. Failure of the amikacin, cefoxitin, and clarithromycin combination regimen for treating pulmonary mycobacterium abscessus infection. Antimicrob Agents Chemother. 2016;60(10):6374–6.PubMedPubMedCentralCrossRef
79.
Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38(11):1538–44.PubMedCrossRef
80.
Modongo C, Pasipanodya JG, Zetola NM, Williams SM, Sirugo G, Gumbo T. Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients. Antimicrob Agents Chemother. 2015;59(10):6337–43.PubMedPubMedCentralCrossRef
81.
Nichols DP, Odem-Davis K, Cogen JD, Goss CH, Ren CL, Skalland M, et al. Pulmonary outcomes associated with long-term azithromycin therapy in cystic fibrosis. Am J Respir Crit Care Med. 2020;201(4):430–7.PubMedPubMedCentralCrossRef
82.
Cooper MA, Nye K, Andrews JM, Wise R. The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin. J Antimicrob Chemother. 1990;26(4):533–8.PubMedCrossRef
83.
Wilms EB, Touw DJ, Heijerman HG, van der Ent CK. Azithromycin maintenance therapy in patients with cystic fibrosis: a dose advice based on a review of pharmacokinetics, efficacy, and side effects. Pediatr Pulmonol. 2012;47(7):658–65.PubMedCrossRef
84.
Wilms EB, Touw DJ, Heijerman HG. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis. Ther Drug Monit. 2006;28(2):219–25.PubMedCrossRef
85.
Cipolli M, Cazzola G, Novelli A, Cassetta M, Fallani S, Mazzei T. Azithromycin concentrations in serum and bronchial secretions of patients with cystic fibrosis. Clin Drug Invest. 2001;21(5):353–60.CrossRef
86.
Shimomura H, Andachi S, Aono T, Kigure A, Yamamoto Y, Miyajima A, et al. Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes. J Pharm Health Care Sci. 2015;1:32.PubMedPubMedCentralCrossRef
87.
Deshpande D, Pasipanodya JG, Gumbo T. Azithromycin dose to maximize efficacy and suppress acquired drug resistance in pulmonary Mycobacterium avium disease. Antimicrob Agents Chemother. 2016;60(4):2157–63.PubMedPubMedCentralCrossRef
88.
Choi GE, Shin SJ, Won CJ, Min KN, Oh T, Hahn MY, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med. 2012;186(9):917–25.PubMedCrossRef
89.
Richard M, Gutiérrez AV, Kremer L. Dissecting erm(41)-mediated macrolide-inducible resistance in Mycobacterium abscessus. Antimicrob Agents Chemother. 2020;64(2):e01879-e1919.PubMedPubMedCentralCrossRef
90.
91.
Dalboge CS, Nielsen XC, Dalhoff K, Alffenaar JW, Duno M, Buchard A, et al. Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. J Cyst Fibros. 2014;13(2):179–85.PubMedCrossRef
92.
Schon T, Chryssanthou E. Minimum inhibitory concentration distributions for Mycobacterium avium complex-towards evidence-based susceptibility breakpoints. Int J Infect Dis. 2017;55:122–4.PubMedCrossRef
93.
94.
Guo Q, Chu H, Ye M, Zhang Z, Li B, Yang S, et al. The clarithromycin susceptibility genotype affects the treatment outcome of patients with Mycobacterium abscessus lung disease. Antimicrob Agents Chemother. 2018;62(5):e02360-e2417.PubMedPubMedCentralCrossRef
95.
Li H, Tong L, Wang J, Liang Q, Zhang Y, Chu N, et al. An intensified regimen containing linezolid could improve treatment response in Mycobacterium abscessus lung disease. Biomed Res Int. 2019;2019:8631563.PubMedPubMedCentralCrossRef
96.
Brown-Elliott BA, Wallace RJ Jr. In vitro susceptibility testing of tedizolid against nontuberculous mycobacteria. J Clin Microbiol. 2017;55(6):1747–54.PubMedPubMedCentralCrossRef
97.
Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, et al. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob Agents Chemother. 2011;55(7):3393–8.PubMedPubMedCentralCrossRef
98.
99.
Santos RP, Prestidge CB, Brown ME, Urbancyzk B, Murphey DK, Salvatore CM, et al. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Pediatr Pulmonol. 2009;44(2):148–54.PubMedCrossRef
100.
Nuermberger E. Evolving strategies for dose optimization of linezolid for treatment of tuberculosis. Int J Tuberc Lung Dis. 2016;20(12):48–51.PubMedCrossRef
101.
World Health Organization. Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Contract No.: 2018 (WHO/CDS/TB/2018.5). Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization; 2018.
102.
Zhang Z, Lu J, Song Y, Pang Y. In vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex. Diagn Microbiol Infect Dis. 2018;90(1):31–4.PubMedCrossRef
103.
Rao GG, Konicki R, Cattaneo D, Alffenaar JW, Marriott DJE, Neely M. Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2020;42(1):83–92.PubMedCrossRef
104.
Cattaneo D, Orlando G, Cozzi V, Cordier L, Baldelli S, Merli S, et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents. 2013;41(6):586–9.PubMedCrossRef
105.
Song T, Lee M, Jeon HS, Park Y, Dodd LE, Dartois V, et al. Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis. EBioMedicine. 2015;2(11):1627–33.PubMedPubMedCentralCrossRef
106.
Shoen C, Benaroch D, Sklaney M, Cynamon M. In vitro activities of omadacycline against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2019;63(5):e02522-e2618.PubMedPubMedCentralCrossRef
107.
Gotfried MH, Horn K, Garrity-Ryan L, Villano S, Tzanis E, Chitra S, et al. Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects. Antimicrob Agents Chemother. 2017;61(9):e01137-e1217.CrossRef
108.
Wallace RJ Jr, Dukart G, Brown-Elliott BA, Griffith DE, Scerpella EG, Marshall B. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother. 2014;69(7):1945–53.PubMedPubMedCentralCrossRef
109.
Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58(2):256–65.PubMedCrossRef
110.
Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol. 2011;7(11):1459–70.PubMedCrossRef
111.
Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, et al. Tigecycline is highly efficacious against Mycobacterium abscessus pulmonary disease. Antimicrob Agents Chemother. 2016;60(5):2895–900.PubMedPubMedCentralCrossRef
112.
Kwon YS, Levin A, Kasperbauer SH, Huitt GA, Daley CL. Efficacy and safety of tigecycline for Mycobacterium abscessus disease. Respir Med. 2019;158:89–91.PubMedCrossRef
113.
Pryjma M, Burian J, Thompson CJ. Rifabutin acts in synergy and is bactericidal with frontline Mycobacterium abscessus antibiotics clarithromycin and tigecycline, suggesting a potent treatment combination. Antimicrob Agents Chemother. 2018;62(8):e00283-e318.PubMedPubMedCentralCrossRef
114.
Cheng A, Tsai YT, Chang SY, Sun HY, Wu UI, Sheng WH, et al. In vitro synergism of rifabutin with clarithromycin, imipenem and tigecycline against the Mycobacterium abscessus complex. Antimicrob Agents Chemother. 2019;63(4):e02234-e2318.PubMedPubMedCentralCrossRef
115.
116.
Ruth MM, Sangen JJN, Pennings LJ, Schildkraut JA, Hoefsloot W, Magis-Escurra C, et al. Minocycline has no clear role in the treatment of Mycobacterium abscessus disease. Antimicrob Agents Chemother. 2018;62(10):e01208-e1218.PubMedPubMedCentralCrossRef
117.
Ruth MM, Magombedze G, Gumbo T, Bendet P, Sangen JJN, Zweijpfenning S, et al. Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. J Antimicrob Chemother. 2019;74(7):1952–61.PubMedCrossRef
118.
119.
Magis-Escurra C, Later-Nijland HM, Alffenaar JW, Broeders J, Burger DM, van Crevel R, et al. Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. Int J Antimicrob Agents. 2014;44(3):229–34.PubMedCrossRef
120.
Abulfathi AA, Decloedt EH, Svensson EM, Diacon AH, Donald P, Reuter H. Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis. Clin Pharmacokinet. 2019;58(9):1103–29.PubMedCrossRef
121.
Chen J, Raymond K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob. 2006;5:3.PubMedPubMedCentralCrossRef
122.
Naidoo A, Naidoo K, McIlleron H, Essack S, Padayatchi N. A review of moxifloxacin for the treatment of drug-susceptible tuberculosis. J Clin Pharmacol. 2017;57(11):1369–86.PubMedPubMedCentralCrossRef
123.
Jordan CL, Noah TL, Henry MM. Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis. Pediatr Pulmonol. 2016;51(S44):S61-s70.PubMedCrossRef
124.
Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 2013;69(5):1091–101.PubMedCrossRef
125.
Berge M, Guillemain R, Tregouet DA, Amrein C, Boussaud V, Chevalier P, et al. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Eur J Clin Pharmacol. 2011;67(3):253–60.PubMedCrossRef
126.
van Ingen J, Hoefsloot W, Mouton JW, Boeree MJ, van Soolingen D. Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance. Int J Antimicrob Agents. 2013;42(1):80–2.PubMedCrossRef
127.
Aziz DB, Low JL, Wu ML, Gengenbacher M, Teo JWP, Dartois V, et al. Rifabutin is active against Mycobacterium abscessus Complex. Antimicrob Agents Chemother. 2017;61(6):e00155-e217.PubMedPubMedCentralCrossRef
128.
Jonsson S, Davidse A, Wilkins J, Van der Walt JS, Simonsson US, Karlsson MO, et al. Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob Agents Chemother. 2011;55(9):4230–7.PubMedPubMedCentralCrossRef
129.
Varughese A, Brater DC, Benet LZ, Lee CS. Ethambutol kinetics in patients with impaired renal function. Am Rev Respir Dis. 1986;134(1):34–8.PubMed
130.
Hall RG 2nd, Swancutt MA, Meek C, Leff RD, Gumbo T. Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. Antimicrob Agents Chemother. 2012;56(3):1502–7.PubMedPubMedCentralCrossRef
131.
Kim HJ, Lee JS, Kwak N, Cho J, Lee CH, Han SK, et al. Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease. BMC Pulm Med. 2019;19(1):212.PubMedPubMedCentralCrossRef
132.
Deshpande D, Srivastava S, Meek C, Leff R, Gumbo T. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob Agents Chemother. 2010;54(5):1728–33.PubMedPubMedCentralCrossRef
133.
Kwon BS, Kim MN, Sung H, Koh Y, Kim WS, Song JW, et al. In vitro MIC values of rifampin and ethambutol and treatment outcome in Mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2018;62(10):e00491-e518.PubMedPubMedCentralCrossRef
134.
Ferro BE, Meletiadis J, Wattenberg M, de Jong A, van Soolingen D, Mouton JW, et al. Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin. Antimicrob Agents Chemother. 2016;60(2):1097–105.PubMedPubMedCentralCrossRef
135.
Reddy VM, O’Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother. 1999;43(5):615–23.PubMedCrossRef
136.
van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother. 2012;56(12):6324–7.PubMedPubMedCentralCrossRef
137.
Schwartz M, Fisher S, Story-Roller E, Lamichhane G, Parrish N. Activities of dual combinations of antibiotics against multidrug-resistant nontuberculous mycobacteria recovered from patients with cystic fibrosis. Microb Drug Resist. 2018;24(8):1191–7.PubMedPubMedCentralCrossRef
138.
Luo J, Yu X, Jiang G, Fu Y, Huo F, Ma Y, et al. In vitro activity of clofazimine against nontuberculous mycobacteria isolated in Beijing, China. Antimicrobial Agents Chemotherapy. 2018;62(7):e00072-e118.PubMedPubMedCentralCrossRef
139.
Elborn JS, Ramsey BW, Boyle MP, Konstan MW, Huang X, Marigowda G, et al. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respir Med. 2016;4(8):617–26.PubMedPubMedCentralCrossRef
140.
Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220–31.PubMedPubMedCentralCrossRef
141.
Vertex Pharmaceuticals Incorporated. KALYDECO (ivacaftor) product insert.
142.
Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I. Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. food and drug administration between 2013 and 2016. Drug Metab Dispos. 2018;46(6):835–45.PubMedCrossRef
143.
Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol. 2000;50(4):285–95.PubMedPubMedCentralCrossRef
144.
Vertex Pharmaceuticals Incorporated. Orkambi (lumacaftor/ivacaftor) product information. Vertex Phaarmaceuticals Incorporated; 2018.
145.
Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809–19.PubMedPubMedCentralCrossRef
146.
Vertex Pharmaceuticals Incorporated. Investigator’s Brochure: Elexacaftor/Tezacaftor/Ivacaftor(VX-445/VX-661/VX-770). Vertex Pharmaceuticals Incorporated; 2019.
147.
Sangana RGH, Yu Chun D, Einolf H. Evaluation of clinical drug interaction potential of clofazimine using static and dynamic modelling approaches. Drug Metab Depos. 2018;46:26–32.CrossRef
148.
Borowitz D, Lubarsky B, Wilschanski M, Munck A, Gelfond D, Bodewes F, et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation after treatment with ivacaftor. Dig Dis Sci. 2016;61(1):198–207.PubMedCrossRef
149.
Wilms EB, Touw DJ, Heijerman HG. Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients. J Cyst Fibros. 2008;7(1):79–84.PubMedCrossRef
150.
Baumann U, King M, App EM, Tai S, Konig A, Fischer JJ, et al. Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. Can Respir J. 2004;11(2):151–5.PubMedCrossRef
151.
Saralaya D, Peckham DG, Hulme B, Tobin CM, Denton M, Conway S, et al. Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis. J Antimicrob Chemother. 2004;53(2):325–8.PubMedCrossRef
152.
Illamola SM, Huynh HQ, Liu X, Bhakta ZN, Sherwin CM, Liou TG, et al. Population pharmacokinetics of amikacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2018;62(10):e00877-e918.PubMedPubMedCentralCrossRef
153.
Byl B, Baran D, Jacobs F, Herschuelz A, Thys JP. Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients. J Antimicrob Chemother. 2001;48(2):325–7.PubMedCrossRef
154.
Grenier B, Autret E, Marchand S, Thompson R. Kinetic parameters of amikacin in cystic fibrosis children. Infection. 1987;15(4):295–9.PubMedCrossRef
155.
Bergan T, Michalsen H, Malmborg AS, Pedersen SS, Pressler T, Storrosten OT, et al. Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis. Chemotherapy. 1993;39(6):369–73.PubMedCrossRef
156.
Sanofi-Aventis. Rifampicin product insert. Paris: Sanofi-Aventis; 2017.
157.
Stott KE, Pertinez H, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran G, et al. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. J Antimicrob Chemother. 2018;73(9):2305–13.PubMedPubMedCentralCrossRef
158.
Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2003;47(7):2118–24.PubMedPubMedCentralCrossRef
159.
Schon T, Jureen P, Giske CG, Chryssanthou E, Sturegard E, Werngren J, et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother. 2009;64(4):786–93.PubMedCrossRef
160.
Dura Pharmaceuticals. Ethambutol package insert. San Diego: Dura Pharmaceuticals; 2001.
161.
McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother. 2006;50(4):1170–7.PubMedPubMedCentralCrossRef
162.
Burkhardt O, Borner K, Stass H, Beyer G, Allewelt M, Nord CE, et al. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand J Infect Dis. 2002;34(12):898–903.PubMedCrossRef
163.
Reed MD, Blumer JL. Azithromycin: a critical review of the first azilide antibiotic and its role in pediatric practice. Pediatr Infect Dis J. 1997;16(11):1069–83.PubMedCrossRef
164.
Deshpande D, Srivastava S, Meek C, Leff R, Hall GS, Gumbo T. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. Antimicrob Agents Chemother. 2010;54(6):2534–9.PubMedPubMedCentralCrossRef
165.
Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52(3):852–7.PubMedCrossRef
166.
Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy. 2001;21(10 Pt 2):233s-s252.PubMedCrossRef
167.
Grayson L, editor. Kucers’ the use of antibiotics. 6th ed. London: Hodder Arnold; 2010.
168.
van Ingen J, van der Laan T, Dekhuijzen R, Boeree M, van Soolingen D. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. Int J Antimicrob Agents. 2010;35(2):169–73.PubMedCrossRef
169.
Novartis Pharmaceutical Incorporated. Clofazimine (Lamprene) product information. New Jersey: Novartis Pharmaceutical Incorporated; 2016.
170.
Swanson RV, Adamson J, Moodley C, Ngcobo B, Ammerman NC, Dorasamy A, et al. Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2015;59(6):3042–51.PubMedPubMedCentralCrossRef
171.
Clarke JT, Libke RD, Regamey C, Kirby WM. Comparative pharmacokinetics of amikacin and kanamycin. Clin Pharmacol Ther. 1974;15(6):610–6.PubMedCrossRef
172.
Chua KY, Bustamante A, Jelfs P, Chen SC, Sintchenko V. Antibiotic susceptibility of diverse Mycobacterium abscessus complex strains in New South Wales. Australia Pathology. 2015;47(7):678–82.PubMed
173.
Acocella G. Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis. 1983;5(Suppl 3):S428–32.PubMedCrossRef
174.
Kucers’ the use of antibiotics. a clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs. 7th ed. Boca Raton: CRC Press; 2018.
175.
Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother. 1999;43(3):568–72.PubMedPubMedCentralCrossRef
176.
Zhu M, Burman WJ, Starke JR, Stambaugh JJ, Steiner P, Bulpitt AE, et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis. 2004;8(11):1360–7.PubMed
177.
Jeong BH, Jeon K, Park HY, Moon SM, Kim SY, Lee SY, et al. Peak plasma concentration of azithromycin and treatment responses in Mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2016;60(10):6076–83.PubMedPubMedCentralCrossRef
178.
Alffenaar JW, Kosterink JG, van Altena R, van der Werf TS, Uges DR, Proost JH. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit. 2010;32(1):97–101.PubMedCrossRef
179.
Buerger C, Plock N, Dehghanyar P, Joukhadar C, Kloft C. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother. 2006;50(7):2455–63.PubMedPubMedCentralCrossRef
180.
Watanabe A, Anzai Y, Niitsuma K, Saito M, Yanase K, Nakamura M. Penetration of minocycline hydrochloride into lung tissue and sputum. Chemotherapy. 2001;47(1):1–9.PubMedCrossRef
181.
Pharmaceuticals T. Minocycline hydrochloride product insert. Cranford: Triax Pharmaceuticals; 2010.
182.
Cholo MC, Mothiba MT, Fourie B, Anderson R. Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline. J Antimicrob Chemother. 2017;72(2):338–53.PubMedCrossRef
183.
Nix DE, Adam RD, Auclair B, Krueger TS, Godo PG, Peloquin CA. Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis (Edinb). 2004;84(6):365–73.PubMedCrossRef
184.
185.
Lee H, Sohn YM, Ko JY, Lee SY, Jhun BW, Park HY, et al. Once-daily dosing of amikacin for treatment of Mycobacterium abscessus lung disease. Int J Tuberc Lung Dis. 2017;21(7):818–24.PubMedCrossRef
186.
Barbour A, Schmidt S, Ma B, Schiefelbein L, Rand KH, Burkhardt O, et al. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet. 2009;48(9):575–84.PubMedCrossRef
187.
Vic P, Ategbo S, Turck D, Husson M, Tassin E, Loeuille G, Deschildre A, Druon D, Elian J, Arrouet-Lagandre C, Farriaux J. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in custic fibrosis patients. Eur J Paeds. 1996;155:948–53.CrossRef
Metadata
Title
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis
Authors
Andrew Burke
Daniel Smith
Chris Coulter
Scott C. Bell
Rachel Thomson
Jason A. Roberts
Publication date
01-09-2021
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 9/2021
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-021-01010-4

Other articles of this Issue 9/2021

Clinical Pharmacokinetics 9/2021 Go to the issue

Original Research Article

Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis

Correction

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

Original Research Article

Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects

Original Research Article

An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis

Review Article

Clinical Pharmacokinetics of Triazoles in Pediatric Patients

Original Research Article

Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin® in Children and Adults